Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
2007
mi
from 98109
Columbus, OH
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
2007
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Toledo Medical Center
1927
mi
from 98109
Toledo, OH
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Toledo Medical Center
1927
mi
from 98109
Toledo, OH
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Oklahoma Medical Research Foundation
1523
mi
from 98109
Oklahoma City, OK
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Oklahoma Medical Research Foundation
1523
mi
from 98109
Oklahoma City, OK
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
2206
mi
from 98109
Duncansville, PA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
2206
mi
from 98109
Duncansville, PA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania Health Systems
2373
mi
from 98109
Philadelphia, PA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania Health Systems
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
2134
mi
from 98109
Pittsburgh, PA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Low Country Rheumatology
2423
mi
from 98109
Charleston, SC
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Low Country Rheumatology
2423
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Austin Regional Clinic
1766
mi
from 98109
Austin, TX
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Austin Regional Clinic
1766
mi
from 98109
Austin, TX
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
1884
mi
from 98109
Houston, TX
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
1884
mi
from 98109
Houston, TX
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
The Seattle Arthritis Clinic
7
mi
from 98109
Seattle, WA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
The Seattle Arthritis Clinic
7
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Dermatology Institute and Skin Care Center
961
mi
from 98109
Santa Monica, CA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Dermatology Institute and Skin Care Center
961
mi
from 98109
Santa Monica, CA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Los Angeles Biomedical Research Institute at Harbor-UCLA
976
mi
from 98109
Torrance, CA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Los Angeles Biomedical Research Institute at Harbor-UCLA
976
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center
2402
mi
from 98109
New York, NY
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
2161
mi
from 98109
Rochester, NY
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
DJL Clinical Research
2284
mi
from 98109
Charlotte, NC
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
DJL Clinical Research
2284
mi
from 98109
Charlotte, NC
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Emory University School of Medicine
2180
mi
from 98109
Atlanta, GA
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Emory University School of Medicine
2180
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Feinstein Institute, North Shore Hospital
2401
mi
from 98109
Manhasset, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Feinstein Institute, North Shore Hospital
2401
mi
from 98109
Manhasset, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
2402
mi
from 98109
New York, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical College: Hospital for Special Surgery -
2402
mi
from 98109
New York, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical College: Hospital for Special Surgery -
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
2401
mi
from 98109
New York, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of North Carolina School of Medicine
2337
mi
from 98109
Chapel Hill, NC
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of North Carolina School of Medicine
2337
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
2008
mi
from 98109
Columbus, OH
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
2008
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern
1677
mi
from 98109
Dallas, TX
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern
1677
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center: Division of Rheumatology
962
mi
from 98109
Los Angeles, CA
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center: Division of Rheumatology
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver: School of Medicine: Division of Rheumatology
mi
from 98109
Aurora, CO
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver: School of Medicine: Division of Rheumatology
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Colorado Kidney Care
1021
mi
from 98109
Denver, CO
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Colorado Kidney Care
1021
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
1716
mi
from 98109
Saint Louis, MO
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
1716
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Rheumatology Associates Of North Alabama, P.C.
2038
mi
from 98109
Huntsville, AL
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Rheumatology Associates Of North Alabama, P.C.
2038
mi
from 98109
Huntsville, AL
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
979
mi
from 98109
Long Beach, CA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
979
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Harbor UCLA Medical Center
976
mi
from 98109
Torrance, CA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Harbor UCLA Medical Center
976
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
2424
mi
from 98109
Farmington, CT
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
2424
mi
from 98109
Farmington, CT
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Center for Rheumatology, Immunology and Arthritis
2717
mi
from 98109
Fort Lauderdale, FL
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Center for Rheumatology, Immunology and Arthritis
2717
mi
from 98109
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
The Arthritis Center
2508
mi
from 98109
Palm Harbor, FL
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
The Arthritis Center
2508
mi
from 98109
Palm Harbor, FL
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
1440
mi
from 98109
Wichita, KA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
1440
mi
from 98109
Wichita, KA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Med. Center Div. Of Gastroenterology
2483
mi
from 98109
Boston, MA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Med. Center Div. Of Gastroenterology
2483
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Physician Research Collaboration
1346
mi
from 98109
Lincoln, NE
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Physician Research Collaboration
1346
mi
from 98109
Lincoln, NE
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Albuquerque Clinical Trials
1184
mi
from 98109
Albuquerque, NM
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Albuquerque Clinical Trials
1184
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
North Shore-LIJ Health System
2412
mi
from 98109
Great Neck, NY
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
North Shore-LIJ Health System
2412
mi
from 98109
Great Neck, NY
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
The Feinstein Institute for Medical Research
2413
mi
from 98109
Manhasset, NY
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
The Feinstein Institute for Medical Research
2413
mi
from 98109
Manhasset, NY
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Joint And Muscle Medical Care And Research Institute (Jmmcri)
2282
mi
from 98109
Charlotte, NC
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Joint And Muscle Medical Care And Research Institute (Jmmcri)
2282
mi
from 98109
Charlotte, NC
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Pmg Research Of Salisbury
2281
mi
from 98109
Salisbury, NC
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Pmg Research Of Salisbury
2281
mi
from 98109
Salisbury, NC
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
East Penn Rheumatology Associates, P.C.
2342
mi
from 98109
Bethlehem, PA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
East Penn Rheumatology Associates, P.C.
2342
mi
from 98109
Bethlehem, PA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Allegheny-Singer Research Institute (Asri)
2132
mi
from 98109
Pittsburgh, PA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Allegheny-Singer Research Institute (Asri)
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Tekton Research
1770
mi
from 98109
Austin, TX
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Tekton Research
1770
mi
from 98109
Austin, TX
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Arthritis Northwest
228
mi
from 98109
Spokane, WA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Arthritis Northwest
228
mi
from 98109
Spokane, WA
Click here to add this to my saved trials